Company Overview - Rafael Holdings, Inc. (NYSE:RFL) focuses on the development and commercialization of novel cancer therapies through its subsidiaries, emphasizing oncology drug research and development [1] Financial Performance - RFL's Return on Invested Capital (ROIC) is -34.90%, significantly lower than its Weighted Average Cost of Capital (WACC) of 7.93%, resulting in a ROIC to WACC ratio of -4.40, indicating the company is not generating returns above its cost of capital [2] - Compared to its peers, RFL demonstrates relatively more efficient capital utilization despite the negative ROIC [2] Peer Comparison - Scholar Rock Holding Corporation (SRRK) has a ROIC of -101.98% and a WACC of 6.82%, leading to a ROIC to WACC ratio of -14.96, indicating less efficient capital utilization compared to RFL [3] - Evelo Biosciences, Inc. (EVLO) shows a ROIC of -199.73% and a WACC of 9.04%, resulting in a ROIC to WACC ratio of -22.10, further highlighting its inefficiency [3] - Verrica Pharmaceuticals Inc. (VRCA) is the most efficient among peers with a ROIC to WACC ratio of -4.13, indicating better capital efficiency despite all companies having negative ratios [4] - Replimune Group, Inc. (REPL) has a ROIC of -71.09% and a WACC of 7.47%, resulting in a ROIC to WACC ratio of -9.52, showing less favorable performance [4]

Company Overview - MongoDB, Inc. is a leading player in the database management industry, recognized for its innovative cloud-based solutions and modern, general-purpose database platform designed for developers and their applications [1] Financial Performance - The Return on Invested Capital (ROIC) for MongoDB is -5.15%, while its Weighted Average Cost of Capital (WACC) is 10.25%, resulting in a ROIC to WACC ratio of -0.50, indicating inefficiencies in capital utilization [2] - Compared to its peers, Okta, Inc. shows the most efficient capital utilization with a ROIC of 1.36% and a WACC of 7.09%, leading to a ROIC to WACC ratio of 0.19 [3] Peer Comparison - Other peers like Datadog, Zscaler, and Atlassian also exhibit negative ROIC to WACC ratios. Datadog has a ROIC of -0.78% and a WACC of 9.46%, resulting in a ratio of -0.08. Zscaler's ROIC is -3.00% with a WACC of 8.30%, leading to a ratio of -0.36. Atlassian's ROIC is -6.72% against a WACC of 7.79%, resulting in a ratio of -0.86 [4] - Twilio Inc. shows a slightly positive ROIC to WACC ratio of 0.11, with a ROIC of 1.08% and a WACC of 9.60%, indicating room for improvement in capital utilization [5] Conclusion - The analysis emphasizes the importance of efficient capital management in enhancing financial performance and boosting investor confidence across the industry [5]

Company Overview - Phreesia, Inc. (NYSE:PHR) is a healthcare technology company focused on enhancing patient intake and engagement while streamlining administrative processes in healthcare settings [1][5] - The company operates in a competitive landscape alongside peers such as Health Catalyst, Veracyte, Accolade, Castle Biosciences, and Personalis, each providing unique solutions in the healthcare technology sector [1] Financial Performance - Phreesia's Return on Invested Capital (ROIC) is -12.98%, indicating that the company is not generating returns above its cost of capital [2][5] - The company's Weighted Average Cost of Capital (WACC) is 6.71%, leading to a ROIC to WACC ratio of -1.93, which suggests inefficient capital utilization [2][5] Peer Comparison - Health Catalyst has a ROIC of -16.99% and a WACC of 6.12%, resulting in a ROIC to WACC ratio of -2.78, indicating even less efficient capital utilization than Phreesia [3] - Accolade and Personalis also exhibit negative ROIC to WACC ratios of -2.91 and -3.19, respectively, reflecting similar challenges in generating returns above their cost of capital [3] - Castle Biosciences has a ROIC of -4.44% and a WACC of 8.60%, resulting in a ROIC to WACC ratio of -0.52, which, while still negative, is closer to breaking even compared to other peers [4] Industry Challenges - Overall, Phreesia and its peers face significant challenges in generating sufficient returns to cover their cost of capital, which raises concerns for investors [4]

Core Insights - Semtech Corporation is a leading supplier of high-performance analog and mixed-signal semiconductors, serving various industries including communications, industrial, and consumer markets [1] - The company has a Return on Invested Capital (ROIC) of 6.65%, which is significantly lower than its Weighted Average Cost of Capital (WACC) of 13.35%, indicating potential inefficiencies in capital utilization [1] Comparison with Competitors - Silicon Laboratories has a negative ROIC of -8.95% against a WACC of 10.98%, reflecting an inability to generate positive returns on invested capital [2] - Power Integrations has a ROIC of 2.80% and a WACC of 10.10%, also indicating struggles to cover its cost of capital [2] - Lattice Semiconductor's ROIC is 5.16%, below its WACC of 11.80%, while Diodes Incorporated has a ROIC of 1.34%, far below its WACC of 11.21%, both showing inefficiencies in capital utilization [3]

Core Insights - DigitalBridge Group, Inc. (DBRG) is a global digital infrastructure investment firm focusing on data centers, cell towers, and fiber networks [1] - DBRG's financial performance shows a Return on Invested Capital (ROIC) of 9.30% and a Weighted Average Cost of Capital (WACC) of 10.97%, resulting in a ROIC to WACC ratio of 0.85, indicating inefficiencies in capital utilization [2][6] Comparative Analysis - BrightSpire Capital, Inc. (BRSP) exhibits strong capital efficiency with a ROIC of 26.94% and a WACC of 5.17%, leading to a ROIC to WACC ratio of 5.21, indicating effective value creation [3][6] - Zurn Elkay Water Solutions Corporation (ZWS) shows effective capital utilization with a ROIC of 8.93% and a WACC of 7.45%, resulting in a ROIC to WACC ratio of 1.20, suggesting returns that exceed its cost of capital [4][6] Challenges in the Industry - Alignment Healthcare, Inc. (ALHC) has a ROIC of 0.60% and a WACC of 9.03%, resulting in a low ROIC to WACC ratio of 0.07, indicating significant inefficiencies [5] - Hayward Holdings, Inc. (HAYW) has a ROIC of 6.59% and a WACC of 8.23%, leading to a ratio of 0.80, also indicating less efficient capital use [5]

Mersana Therapeutics, Inc. (NASDAQ:MRSN) is a clinical-stage biopharmaceutical company focused on developing antibody-drug conjugates (ADCs) for cancer treatment. The company aims to improve the lives of patients with cancer by creating innovative therapies. Mersana operates in a competitive landscape alongside companies like Kura Oncology, MacroGenics, Syndax Pharmaceuticals, Deciphera Pharmaceuticals, and Scholar Rock Holding Corporation.In evaluating Mersana's financial efficiency, the Return on Invested ...

Strength and Economic performanceAttempts to justify the unjustifiableThis is a revision of a post originally published July 28, 2025. Thanks go to Michael Ward of Ward Corporate Finance for his collaboration. See >>>Revision below.The topic in this post is cash flow. It is such a reassuringly simple notion. Cash flow is the flow of cash into and out of a company.And I would go so far as to say, understanding cash flow is critical for understanding the financial strength, economic performance and valuations ...

Immunocore Holdings plc (NASDAQ:IMCR) has a Return on Invested Capital (ROIC) of -4.49%, indicating challenges in generating returns above its cost of capital.Compared to its peers, IMCR's ROIC to WACC ratio of -0.68 suggests better capital efficiency, albeit still below the desired threshold.Design Therapeutics, Inc. (DSGN) shows the highest ROIC to WACC ratio among the peers, but IMCR maintains a relatively strong position with potential for improvement in capital utilization.Immunocore Holdings plc (NASD ...

Core Insights - SandRidge Energy, Inc. is an oil and natural gas company focused on hydrocarbon exploration and production in the Mid-Continent region, competing with firms like Range Resources, Chesapeake Energy, Southwestern Energy, SM Energy, and Northern Oil and Gas [1] Financial Performance - SandRidge Energy has a Return on Invested Capital (ROIC) of 11.19% and a Weighted Average Cost of Capital (WACC) of 6.02%, resulting in a ROIC to WACC ratio of 1.86, indicating strong value creation for shareholders [2][6] - In comparison, Range Resources has a ROIC of 9.89% and a WACC of 5.90%, leading to a ROIC to WACC ratio of 1.68, which is lower than SandRidge's [3] - Chesapeake Energy shows a ROIC of 3.89% and a WACC of 5.74%, resulting in a ROIC to WACC ratio of 0.68, indicating underperformance compared to SandRidge [4] - Southwestern Energy and SM Energy have negative ROIC to WACC ratios, further emphasizing SandRidge's superior performance [4] - Northern Oil and Gas has a ROIC of 6.32% and a WACC of 7.39%, yielding a ROIC to WACC ratio of 0.86, which is still below SandRidge's performance [5]

Core Insights - Verrica Pharmaceuticals Inc. is facing significant challenges in capital efficiency, as indicated by its financial metrics [1] - The company's Return on Invested Capital (ROIC) is -65.23%, which is substantially lower than its Weighted Average Cost of Capital (WACC) of 15.85% [2] - This results in a ROIC to WACC ratio of -4.11, highlighting inefficiencies in capital utilization [2] Comparison with Peers - Y-mAbs Therapeutics, Inc. has a ROIC of -27.64% and a WACC of 6.23%, leading to a less negative ROIC to WACC ratio of -4.44, indicating relatively better capital efficiency compared to Verrica [3] - Scholar Rock Holding Corporation and Crinetics Pharmaceuticals, Inc. have even more negative ROIC to WACC ratios of -15.28 and -9.15, respectively, suggesting greater inefficiencies in their capital utilization [4] - Kezar Life Sciences, Inc. also shows a significant negative ratio of -11.75, emphasizing the challenges faced by these companies in generating returns above their cost of capital [4] Overall Analysis - All companies analyzed are experiencing negative ROIC, but Y-mAbs Therapeutics shows the most potential for improvement in capital efficiency [5] - Investors should consider these metrics alongside other financial and strategic factors when evaluating investment opportunities in these companies [5]